( on PROVE 2 data regimens thatmay exc...)Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C,Health

on PROVE 2 data, regimens that may exclude RBV. Vertex expects to focus on treatment durations of no more than 24 weeks. Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. The registration strategy and timing of an NDA filing will be dependent on discussions with regulatory authorities.

PROVE 1 Results at EASL

Interim 12-week antiviral analysis of PROVE 1

A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) in the study. A total of 175 patients received at least one dose of telaprevir in 1 of 3 arms (treatment arms B, C and D) and 75 patients received at least one dose of placebo (arm A). Treatment with telaprevir resulted in a high proportion of patients achieving a rapid viral response at 4 weeks. At the time of the interim analysis, all patients had either completed 12 weeks or discontinued from the study prior to week 12. Available 4-week and 12-week results are detailed in the following table: -0-

 Interim HCV RNA results for Patients Enrolled in the PROVE 1 Trial

---------------------------------------------------------------------

Treatment Assignment            Patients Patients Patients Patients

                                 with     with     with     with HCV

                                 HCV RNA  HCV RNA  HCV RNA  RNA (less

                                 (less    (less    (less    than)10

                                 than)30  than)10  than)10  IU/mL at

                                 IU/mL    IU/mL    IU/mL    end of 12

                                 at end   at end   at end   weeks of

                                 of 4     of 4     of 12    dosing

                                 weeks    weeks    weeks    (last on-

                 
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For
AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference
Between Avandia and Standard Therapy in Risk of Cardiovascular
Hospitalization or Death